IL6 and COVID-19: However, when tocilizumab, a humanised anti-human IL-6 receptor antibody, was pre-incubated in the COVID-19 patient’s plasma, this effect was significantly blunted, indicating that IL-6 and IL-6R may contribute to the hypercoagulability observed in clinical settings [198].